论文部分内容阅读
化疗在治疗非小细胞肺癌 (NSCLC)中占有重要地位 ,但其联合化疗的有效率也只有 30 %～ 4 0 % ,并且这个水平已达到了一个新的平台阶段。影响肺癌患者化疗疗效的主要原因是肿瘤细胞对抗癌药的抗药性 ,其耐药机制非常复杂 ,与耐药基因MDR1、MRP、LRP ,GST、拓扑异构酶Ⅱ质和量的改变、β 微管蛋白基因突变、FGF等多种因素有关。前瞻性进行分子指标的测定 ,是指导肺癌患者化疗用药、进行个体化治疗、提高化疗疗效的关键
Chemotherapy plays an important role in the treatment of non-small cell lung cancer (NSCLC), but the combined chemotherapy is effective only 30% ~ 40%, and this level has reached a new platform stage. The main reason for the effect of chemotherapy in lung cancer patients is the resistance of tumor cells to anticancer drugs, the mechanism of its resistance is very complex, and drug resistance genes MDR1, MRP, LRP, GST, topoisomerase Ⅱ quality and quantity changes, β Tubulin gene mutation, FGF and other factors. Prospective molecular markers, is to guide chemotherapy in patients with lung cancer, individualized treatment, improve the key to the efficacy of chemotherapy